Psoriasis Explained: What’s Driving the Plaques, Why It’s a Systemic Disease, and What Modern Treatment Can Do

Psoriasis affects approximately 8 million Americans and roughly 3% of the global population. It’s one of the most visible and one of the most misunderstood chronic conditions in medicine. People often assume it’s a superficial skin problem – something that just needs the right cream. The reality is that psoriasis is a systemic immune-mediated disease with consequences well beyond the skin, and it has seen some of the most dramatic treatment advances in all of dermatology over the past decade.

What Psoriasis Is

Psoriasis is a chronic, immune-driven condition characterized by dramatically accelerated skin cell turnover. Normal skin cells complete their cycle from production to shedding in approximately 28-30 days. In psoriatic skin, this cycle is compressed to just 3-5 days – cells are produced so rapidly that they accumulate on the skin surface before they can mature and shed normally, forming the thick, scaly plaques characteristic of the condition.

This accelerated turnover is not a skin cell malfunction – it’s driven by immune signals. Specifically, dysregulated T cells (particularly Th17 cells) produce cytokines – primarily IL-17A, IL-23, and TNF-alpha – that stimulate keratinocytes (skin cells) to proliferate at an abnormal rate and drive the inflammation visible in psoriatic plaques.

Types of Psoriasis

Plaque Psoriasis (Psoriasis Vulgaris)

The most common form, accounting for approximately 80-90% of cases. Characterized by well-defined, raised plaques with silvery-white scale – typically appearing on the elbows, knees, scalp, and lower back. The plaques represent the accumulation of rapidly produced, incompletely matured skin cells.

Plaques can range from a few small patches to extensive involvement across the entire body surface. The scale can be removed (it’s loosely adherent), revealing a shiny red surface that may bleed with minor trauma (Auspitz sign).

Scalp Psoriasis

Affects approximately 50% of people with psoriasis at some point. Can appear as isolated scalp involvement without other skin plaques. Ranges from fine scaling to thick, crusted plaques covering the entire scalp – extending beyond the hairline onto the forehead, neck, and around the ears. A significant cause of hair loss through traction from scale and inflammation.

Nail Psoriasis

Nail involvement occurs in approximately 50% of people with psoriasis and up to 80-90% of those with psoriatic arthritis. Features include:

• Pitting (small depressions in the nail surface)
• Onycholysis (nail separating from the nail bed)
• Oil-drop sign (yellow-brown discoloration under the nail)
• Subungual hyperkeratosis (thickening under the nail)
• Nail crumbling

Nail psoriasis is important beyond cosmetics – it causes functional impairment and is a strong predictor of psoriatic arthritis development.

Guttate Psoriasis

Characterized by small, drop-shaped (guttate = Latin for “drop”) lesions scattered across the trunk and limbs. Often triggered by streptococcal throat infection – particularly in children and young adults. May be a first presentation of psoriasis, or occur in someone with existing plaque psoriasis. Often resolves spontaneously but may evolve into chronic plaque psoriasis.

Inverse Psoriasis

Affects skin folds – underarms, under the breasts, groin, and gluteal cleft. Smooth, red, shiny plaques without the typical silvery scale (scale doesn’t form in moist areas). Often misdiagnosed as a fungal infection. Particularly sensitive to irritation and friction.

Pustular Psoriasis

Sterile (non-infectious) pustules on erythematous skin. Can be localized (palmoplantar pustulosis – on the palms and soles, a debilitating form) or generalized (von Zumbusch – a serious form with widespread pustules, fever, and systemic illness requiring urgent treatment). Distinct from infected skin.

Erythrodermic Psoriasis

A rare but potentially life-threatening form involving widespread erythema (redness) and scaling affecting more than 90% of body surface area. Can cause serious complications including fluid and electrolyte imbalance, protein loss, and cardiovascular strain from the metabolic demands of the inflamed skin. Requires urgent medical management.

Psoriatic Arthritis

Up to 30% of people with psoriasis develop psoriatic arthritis (PsA) – an inflammatory arthritis that can cause joint pain, swelling, stiffness, and potentially permanent joint damage. It’s one of the most important reasons psoriasis should be taken seriously beyond its skin manifestations.

PsA can affect any joint but commonly involves the fingers and toes (dactylitis – “sausage digits”), the distal interphalangeal joints (the joints closest to the fingertip – distinctive for PsA), the spine (spondylitis), and entheses (where tendons and ligaments attach to bone, causing enthesitis – characteristic heel pain, for example).

PsA frequently precedes skin psoriasis or occurs simultaneously. Nail psoriasis is a strong predictor – approximately 80% of people with psoriatic arthritis have nail involvement.

Early identification and treatment of PsA is critical because untreated disease causes progressive, irreversible joint damage. Any joint symptoms in someone with psoriasis warrant rheumatological evaluation.

Psoriasis as a Systemic Disease

The chronic systemic inflammation of psoriasis doesn’t stay in the skin. It drives increased risk of several serious conditions – a reality that has transformed how dermatologists think about psoriasis management.

Cardiovascular disease: People with severe psoriasis have approximately 50-60% higher risk of major cardiovascular events (MI, stroke) compared to the general population. The shared pathway: systemic TNF-alpha, IL-17, and IL-6 from psoriatic inflammation contribute to endothelial dysfunction, atherosclerosis, and cardiovascular risk. The cardiovascular risk is comparable to type 2 diabetes as an independent risk factor.

Metabolic syndrome: Psoriasis is associated with higher rates of obesity, hypertension, dyslipidemia, and type 2 diabetes – through shared inflammatory pathways and bidirectional relationships between adipose tissue inflammation and psoriatic disease.

Non-alcoholic fatty liver disease (MASLD): Significantly more prevalent in psoriasis, partly through shared metabolic risk factors and partly through methotrexate use (which can cause liver fibrosis with prolonged use).

Depression and anxiety: Approximately 30% of people with psoriasis have depression or anxiety – driven by the visible nature of the condition, chronic disease burden, sleep disruption, and direct neuroinflammatory pathways. Psoriasis on visible areas (face, hands) is particularly associated with psychological burden.

Inflammatory bowel disease: Crohn’s disease in particular shares genetic susceptibility and inflammatory pathways with psoriasis – co-occurrence is more than coincidental.

Treating psoriasis is not just about clearing the skin. Effective systemic anti-inflammatory treatment may reduce cardiovascular risk alongside skin and joint outcomes. This is one of the arguments for treating moderate-to-severe psoriasis with systemic therapy rather than accepting inadequate control.

Triggers and Factors That Worsen Psoriasis

Psoriasis is not caused by these factors – but they can trigger flares or worsen existing disease:

• Stress: One of the most consistently reported triggers – neurogenic inflammation and stress hormones amplify the immune response
• Infections: Streptococcal infections commonly trigger guttate psoriasis; other infections can worsen plaque psoriasis
• Medications: Beta-blockers, lithium, antimalarials (hydroxychloroquine), NSAIDs, and sudden withdrawal of systemic corticosteroids can all trigger or worsen psoriasis
• Trauma to the skin (Koebner phenomenon): Psoriasis can develop at sites of skin injury – cuts, burns, surgical scars, sunburn
• Alcohol: Worsens psoriasis through multiple mechanisms including reduced treatment efficacy and direct immune effects; also a contraindication concern with methotrexate
• Smoking: Independent risk factor for psoriasis severity and a contraindication concern for some treatments
• Obesity: Worsens psoriasis severity and reduces response to biologic therapy

Treatment: The Most Transformed Field in Dermatology

Psoriasis treatment has been revolutionized by the development of targeted biologics over the past two decades. The understanding of specific cytokine pathways driving psoriasis has allowed development of medications that selectively target those pathways with unprecedented efficacy.

Topical Treatments (Mild-Moderate Disease)

Topical corticosteroids: The most commonly used treatment for limited psoriasis. Reduce inflammation rapidly. Potency selection depends on location and severity. Not suitable for indefinite daily use on large areas.

Vitamin D analogues (calcipotriene/calcipotriol): Slow skin cell proliferation and reduce inflammation. Often combined with topical steroids (the combination product Taclonex/Enstilar is particularly effective).

Topical retinoids (tazarotene): Normalizes keratinocyte differentiation. Often combined with topical steroids to improve efficacy and reduce irritation.

Coal tar: An older treatment – anti-proliferative and anti-inflammatory. Effective but messy, strong-smelling, and stains fabric. Still used, particularly for scalp psoriasis.

Calcineurin inhibitors (tacrolimus, pimecrolimus): Off-label use for inverse psoriasis in skin folds where steroids are problematic.

Phototherapy (Moderate Disease)

Narrowband UVB (NB-UVB): The most commonly used phototherapy – delivers ultraviolet B light at 311-313 nm wavelength, which suppresses the pathological T cell response in psoriatic skin. Effective in approximately 70-80% of patients. Requires 2-3 sessions per week for several months. Available in dermatology offices and home units.

PUVA (psoralen + UVA): Less commonly used now given higher skin cancer risk compared to NB-UVB. Reserved for refractory cases.

Systemic Non-Biologic Treatments

Methotrexate: A folate antagonist that suppresses rapidly dividing immune cells. Used for moderate-to-severe psoriasis and psoriatic arthritis. Weekly low-dose regimen. Requires monitoring of liver function (risk of fibrosis with long-term use) and blood counts. Folic acid supplementation reduces side effects. Highly teratogenic – absolute contraindication in pregnancy.

Cyclosporine: A potent calcineurin inhibitor – rapid onset of action, effective for severe flares. Limited to short-term use (12-16 weeks typically) due to nephrotoxicity and hypertension with prolonged use. Useful for rapid control before transitioning to biologic therapy.

Acitretin: An oral retinoid – reduces skin cell proliferation. Most effective for pustular and erythrodermic psoriasis. Highly teratogenic; women must avoid pregnancy during treatment and for 3 years after stopping.

Apremilast (Otezla): An oral PDE4 inhibitor – moderate efficacy, no required blood monitoring, no teratogenicity concerns. Useful for patients who prefer oral therapy and have mild-moderate disease. Common side effects: nausea and diarrhea, typically improving with time.

Biologic Therapies (Moderate-Severe Disease)

The biologics represent the most significant advance in psoriasis treatment:

TNF-alpha inhibitors (first generation):

• Adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), certolizumab (Cimzia)
• Effective, well-studied long-term safety data
• Require tuberculosis screening before starting; can reactivate latent TB
• Also effective for psoriatic arthritis and other inflammatory conditions

IL-12/23 inhibitor:

• Ustekinumab (Stelara) – blocks the shared p40 subunit of IL-12 and IL-23; dosing every 12 weeks after induction

IL-17A inhibitors:

• Secukinumab (Cosentyx), ixekizumab (Taltz), bimekizumab (Bimzelx – blocks both IL-17A and IL-17F)
• Among the most effective biologics for skin clearance; rapid onset
• Caution in inflammatory bowel disease (may worsen Crohn’s)

IL-23 inhibitors (most selective, most effective):

• Risankizumab (Skyrizi), guselkumab (Tremfya), tildrakizumab (Ilumya)
• Target the p19 subunit of IL-23 specifically
• Outstanding skin clearance rates (PASI 90 in 70-80% of patients)
• Dosing every 8-12 weeks after induction; excellent safety profile
• Currently considered among the most effective psoriasis treatments available

Oral JAK inhibitors:

• Deucravacitinib (Sotyktu) – a selective TYK2 inhibitor; FDA-approved 2022; oral, once-daily
• Icotrokinra and zasocitinib are advancing through trials as next-generation oral options

Frequently Asked Questions

Is psoriasis contagious? No – psoriasis is not contagious in any way. It cannot be spread through skin contact, sharing items, or any other means. It’s an immune-mediated condition with genetic and environmental drivers – not an infection.

Will psoriasis ever go away completely? Psoriasis is a chronic condition that follows a relapsing-remitting course – it tends to flare and then improve, sometimes partially or even fully clearing between flares. Complete long-term remission without treatment is uncommon but occurs in some patients. Modern biologics can maintain clear or near-clear skin in many patients as long as treatment continues.

Does diet affect psoriasis? Some evidence supports that anti-inflammatory dietary patterns (Mediterranean diet) may modestly improve psoriasis severity. Weight loss in patients with obesity consistently improves psoriasis severity and biologic response. Alcohol worsens psoriasis and is a genuine concern with methotrexate use. Gluten-free diet benefits psoriasis specifically in patients with coexisting celiac disease – not in the general psoriasis population.

Should I be concerned about my heart health if I have psoriasis? Yes – particularly with moderate-to-severe psoriasis. Cardiovascular screening including blood pressure, lipids, blood glucose, BMI, and smoking status is recommended for people with psoriasis. Several major cardiology and dermatology societies now recommend considering psoriasis as a cardiovascular risk factor equivalent to diabetes when making cardiovascular risk management decisions.

Are biologics safe for long-term use? The biologics approved for psoriasis have now accumulated over 15-20 years of real-world safety data in some cases (adalimumab since 2004, etanercept since 2002). This data is generally reassuring for long-term use in appropriate patients. All biologics carry increased infection risk (due to immune modulation) and require TB screening before starting. IL-23 inhibitors have a particularly favorable long-term safety profile. Each patient’s individual risk factors should be considered.

Disclaimer

This article is for educational purposes only and does not constitute medical advice. Psoriasis management – particularly for moderate-to-severe disease – should be directed by a qualified dermatologist. Biologic and systemic treatments require medical assessment, monitoring, and prescription.

References

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. The Lancet. 2007;370(9583):263-271. https://doi.org/10.1016/S0140-6736(07)61128-3
2. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. 2019;80(4):1029-1072. https://doi.org/10.1016/j.jaad.2018.11.057
3. Boehncke WH, Schön MP. Psoriasis. The Lancet. 2015;386(9997):983-994. https://doi.org/10.1016/S0140-6736(14)61909-7
4. Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CE. Psoriasis prevalence in adults in the United States. JAMA Dermatology. 2021;157(8):940-946. https://doi.org/10.1001/jamadermatol.2021.2007
5. Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clinics in Dermatology. 2018;36(1):21-28. https://doi.org/10.1016/j.clindermatol.2017.09.005
6. National Psoriasis Foundation. About psoriasis. https://www.psoriasis.org/about-psoriasis/
7. American Academy of Dermatology. Psoriasis treatment. https://www.aad.org/public/diseases/psoriasis/treatment
8. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735-1741. https://doi.org/10.1001/jama.296.14.1735
9. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology. 2008;58(5):826-850. https://doi.org/10.1016/j.jaad.2008.02.039
10. MedlinePlus. Psoriasis. https://medlineplus.gov/psoriasis.html